Background: Circulating levels of pepsinogens have been used in high gastric cancer-
| INTRODUCTION
Gastric cancer is the third leading cause of cancer death worldwide. 1 Endoscopic screening may detect precancerous lesions and asymptomatic cancers for early treatment to reduce disease burden. However, it is not clear which populations have sufficiently risk to warrant this invasive procedure. Current clinical guidelines suggest pepsinogen testing for noninvasive identification of individuals at high cancer risk 2 with potential application to risk stratification both in Asia and Europe. 2, 3 Pepsinogens are pepsin pro-enzymes that may be measured in blood as indirect markers of gastric mucosal changes. 4 Two isozymogens, pepsinogen I (PgI), and pepsinogen II (PgII), are produced in different parts of the stomach. 5 PgI production is exclusively limited to acid-secreting glands of the gastric corpus (proximal stomach) whereas
PgII production is widespread in diverse types of glands throughout the stomach as well as Brunner glands of the duodenum. 6 Thus, mucosal atrophy affecting the gastric corpus leads to decreased levels of PgI while PgII levels tend to be relatively stable. In particular, the presence of mucosal inflammation, also related to H. pylori infection, may increase levels of both PgI and PgII 7 and in some cases result in
normal PgI values when both atrophy and inflammation are present.
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To account for this drawback, a decreased ratio of PgI to PgII (PgI/PgII) is considered to be the best serologic marker of gastric atrophy 2 as used for cancer screening in Japan 9 and increasingly in Europe. 6 Different methods for pepsinogen assessment are used in Eastern and Western countries. Miki and Fujishiro have expressed concerns about translating results between the assays. 10 Therefore, we aimed to compare the widely used pepsinogen assay in Japan with the most popular assay in Europe. We also evaluated another assay manufactured in Russia because this country as well as its neighbors, sharing high burden of gastric cancer, usually favor domestic products. We correlated pepsinogen measurements by these different test systems on the same patient samples, determined sensitivity and specificity to detect gastric atrophy and explored alternative cutoff values to improve performance. and PgI/PgII≤3 for "any" atrophy, and PgI≤30 ng/mL and PgI/PgII≤2
| MATERIALS AND METHODS

| Study population
for "advanced" atrophy. 4 For the ELISA tests, the manufacturers' determined cutoff of PgI/PgII<3 was used.
| Statistical analysis
Pairwise correlations among the three different assays were assessed by Spearman statistics. Assay performance was evaluated by receiver operating curve (ROC) analysis with calculations of area under the curve (AUC) and compared by a nonparametric test. 11 Sensitivity, specificity and overall accuracy were assessed using histological diagnosis as the "gold standard." Three alternative analytical approaches were considered based on: (1) manufacturer-defined cutoffs, (2) ROC-defined cutoffs using minimal Euclidean distance, and (3) optimized cutoffs from the C4.5 algorithm decision tree method 12 with 10-fold cross-validation. In addition, sex-specific cutoffs were considered as a sensitivity analysis.
Statistical analyses were conducted with SPSS Statistics for
Windows software, (version 20.0, IBM Corp., Armonk, NY). The decision tree algorithm was implemented in Weka software. 13 P<.05 was considered statistically significant for all comparisons. Means and standard deviations of PgI, PgII and PgI/PgII by atrophy status are presented in Table 1 . For all three test systems, PgI and PgI/PgII ratios were consistently lower in the patients with corpus atrophy.
| RESULTS
Using the manufacturers' cutoffs of PgI/PgII<3 for Biohit and
Vector Best and PgI/PgII≤3 with PgI≤70 ng/mL for Eiken, 22 (44%) of the 50 patients with atrophy were correctly classified by all three test systems while 12 cases (24%) were missed by all (Figure 2 ). The diagnostic performance of the three tests to detect atrophy is presented in Table 2 . Under various alternative approaches, sensitivities ranged from 44% to 76.0%, specificities from 62.6% to 93.1%, and overall accuracy from 63.1% to 90.3%. These parameters did not systematically vary based on manufacturers', ROC-defined or decision treeoptimized cutoffs. Similarly, sex-specific cutoffs did not substantially modify diagnostic performance (Supplemental Table) . 
| DISCUSSION
The first pepsinogen radioimmunoassay was developed by Samloff et al. in the early 1980s 14 and soon suggested as a potential biomarker of gastric cancer. 15 Pepsinogen testing has been utilized for screening purposes in Japan for decades 9, 16 and more recently in Europe. 6, 17 Current test systems are based on latex-enhanced turbidimetric immunoassay or ELISA technologies. Decreases in either PgI levels or PgI/PgII ratio by latex agglutination test are commonly used for diagnosis of atrophy in Japan, while a decrease in PgI/PgII ratio by ELISA is the accepted criterion in Europe.
Our study has compared diagnostic performance of three widely used pepsinogen test systems and, to the best of our knowledge, represents their first head-to-head comparison on symptomatic individuals with histological assessment of corpus atrophy. Atrophy is defined as grade II-III atrophy in the corpus.
Pg I/I, ratio between pepsinogen I and pepsinogen II; SD, Standard Deviation. 
